


## PNU-282987 free base

Cat. No.:	HY-12560
CAS No.:	711085-63-1
Molecular Formula:	C <sub>14</sub> H <sub>17</sub> ClN <sub>2</sub> O
Molecular Weight:	264.75
Target:	nAChR; 5-HT Receptor
Pathway:	Membrane Transporter/Ion Channel; Neuronal Signaling; GPCR/G Protein
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	PNU-282987 (free base) is a potent $\alpha 7$ nicotinic acetylcholine receptor (nAChR) agonist with an EC <sub>50</sub> of 154 nM. PNU-282987 (free base) is also a functional antagonist of the 5-HT <sub>3</sub> receptor with an IC <sub>50</sub> of 4541 nM. PNU-282987 (free base) can be used for the research of central and peripheral nervous systems <sup>[1]</sup> .									
<b>IC<sub>50</sub> &amp; Target</b>	5-HT <sub>3</sub> Receptor									
<b>In Vitro</b>	<p>PNU-282987 (free base) (Compound C7) displaces the R7 selective antagonist methyllycaconitine (MLA) from rat brain homogenates with a K<sub>i</sub> of 27 nM<sup>[1]</sup>.</p> <p>PNU-282987 has <math>\alpha 7</math> nAChR agonist activity with an EC<sub>50</sub> of 154 nM<sup>[1]</sup>.</p> <p>PNU-282987 also has inhibition for the 5-HT<sub>3</sub> receptor with an IC<sub>50</sub> value of 4541nM<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>									
<b>In Vivo</b>	<p>PNU-282987 (free base) (Compound C7) (i.v.; 1, 3 mg/kg) leads to a reversal of the gating deficit<sup>[1]</sup>.</p> <p>PNU-282987 (30 <math>\mu</math>M) evokes currents in rat hippocampal neurons in a concentration-dependent and MLA blockable manner<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1" data-bbox="341 1396 1518 1638"> <tr> <td>Animal Model:</td> <td>Rats<sup>[1]</sup></td> </tr> <tr> <td>Dosage:</td> <td>1, 3 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>i.v.</td> </tr> <tr> <td>Result:</td> <td>Significantly reversed amphetamine-induced gating deficit.</td> </tr> </table>		Animal Model:	Rats <sup>[1]</sup>	Dosage:	1, 3 mg/kg	Administration:	i.v.	Result:	Significantly reversed amphetamine-induced gating deficit.
Animal Model:	Rats <sup>[1]</sup>									
Dosage:	1, 3 mg/kg									
Administration:	i.v.									
Result:	Significantly reversed amphetamine-induced gating deficit.									

### CUSTOMER VALIDATION

- Cell Death Discov. 2022 Mar 30;8(1):141.
- Mol Med. 2022 Sep 4;28(1):104.
- Eur J Pharmacol. 2021 Mar 31;174067.

- 
- J Pain Res. 2021 Feb 15;14:441-452.
  - Biomed Res. 2017; Special Issue: ISSN 0970.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

---

[1]. Bodnar AL, Discovery and structure-activity relationship of quinuclidine benzamides as agonists of alpha7 nicotinic acetylcholine receptors. J Med Chem. 2005 Feb 24;48(4):905-8.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA